OakChart

Recursion Pharmaceuticals Inc

RXRXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

3.59+0.04 (1.13%)
2026-11-12 04:06 CET
Market cap
2,237.89 USD m
Revenue, TTM
68.23 USD m
Net income, TTM
-475.67 USD m
Free cash flow, TTM
-312.48 USD m
EPS diluted, TTM
-0.89
P/E
-
Compare

Price

RXRX against its 20, 50 and 200-day averages
2050200beat
3.004.005.0035.5M71.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26RXRXclose 3.5920-day 3.7850-day 3.79200-day 3.493.5952w high52w low

31.5% under the 52-week high of 5.24 on 22 Jan 2026. 52-week low 2.77 on 19 May 2026. Last 15 sessions, 32.0% high to low

Volume 0.73× normal · the line is the 50-bar volume average

Profile

RXRX
52-week range, 33% of the way up
2.775.24

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

IndexRUT
Employees600
IPOApr 16, 2021
Beta1.17
ATR, 14d0.35
Rel volume0.73
Short float25.40%
Insider own10.15%
Inst own54.36%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap2.24B
Enterprise Value1.76B
Income-475.67M
Sales68.23M
Book/sh1.61
Cash/sh0.89
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees600
IPOApr 16, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S32.80
P/B2.22
P/C4.02
P/FCF-
EV/EBITDA-
EV/Sales25.74
Quick Ratio5.01
Current Ratio5.01
Debt/Eq0.08
LT Debt/Eq0.06
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.89
EPS next Y-0.83
EPS next Q-0.20
EPS this Y38.81%
EPS next Y6.04%
EPS next 5Y19.05%
EPS past 3/5Y-1.84% -22.39%
Sales past 3/5Y23.30% 79.91%
EPS Y/Y TTM50.69%
Sales Y/Y TTM56.18%
EPS Q/Q39.61%
Sales Q/Q258.49%
EarningsNov 02 AMC
EPS/Sales Surpr.-0.46% 21.94%

Ownership

Insider Own10.15%
Insider Trans-0.60%
Inst Own54.36%
Inst Trans4.52%
ROA-36.29%
ROE-48.72%
ROIC-49.73%
Gross Margin-39.97%
Oper. Margin-725.44%
Profit Margin-697.13%
SMA20-5.08%
SMA50-5.17%
SMA2002.93%
Trades-

Technical

Shs Outstand560.46M
Shs Float560.07M
Short Float25.40%
Short Ratio6.28
Short Interest142.27M
52W High5.24 -31.49%
52W Low2.77 29.60%
Volatility8.25% 9.60%
ATR (14)0.35
RSI (14)46.09
Beta1.17
Rel Volume0.73
Avg Volume22.64M
Volume16,595,498

Performance

Perf Week-7.47%
Perf Month-6.39%
Perf Quarter8.46%
Perf Half Y17.70%
Perf YTD-12.22%
Perf Year-23.78%
Perf 3Y-34.25%
Perf 5Y-79.84%
Perf 10Y-
Recom2.14
Target Price7.32
Prev Close3.55
Price3.59
Change %1.13%

Analyst ratings

latest 10 of 13
DateActionAnalystRating changeTargetImplied
Dec 17, 2025UpgradeJJP MorganNeutral → Overweight$11+206.4%
Jul 03, 2025ResumedMMorgan StanleyEqual-Weight$5+39.3%
May 22, 2023InitiatedMMorgan StanleyEqual-Weight$8+122.8%
Mar 16, 2023InitiatedNNeedhamBuy$17+373.5%
Sep 16, 2022InitiatedKKeyBanc Capital MarketsOverweight$20+457.1%
Apr 18, 2022DowngradeBBofA SecuritiesBuy → Neutral$10+178.6%
Mar 04, 2022DowngradeSSVB LeerinkOutperform → Mkt Perform$10+178.6%
Sep 21, 2021InitiatedBBerenbergBuy$37+930.6%
May 11, 2021InitiatedSSVB LeerinkOutperform$33+819.2%
May 11, 2021InitiatedKKeyBanc Capital MarketsOverweight$36+902.8%

Peers

Mkt cap
TickerCompanyMkt cap
ABSIAbsci Corp1.74B
GENBGenerate Biomedicines Inc1.73B
ABCLAbCellera Biologics Inc3.90B
DNAGinkgo Bioworks Holdings Inc679.14M
RLAYRelay Therapeutics Inc4.36B
EIKNEikon Therapeutics Inc361.28M
HYFTMindWalk Holdings Corp49.00M
TWSTTwist Bioscience Corp8.07B
OABIOmniAb Inc743.89M
LTRNLantern Pharma Inc7.19M

Insider trading

latest 14 of 99
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Borgeson BlakeDirectorNov 03 '26Sale3.8840,000155,2006,068,287Nov 04 05:12 PM
Borgeson BlakeDirectorNov 03 '26Proposed Sale3.8840,000155,200Nov 03 11:24 AM
Borgeson BlakeDirectorOct 06 '26Sale4.8450,000242,0006,108,287Oct 07 06:08 PM
HERSHBERG ROBERTDirectorOct 06 '26Option Exercise2.2225,00055,500187,156Oct 07 06:08 PM
HERSHBERG ROBERTDirectorOct 06 '26Sale5.0025,000125,000162,156Oct 07 06:08 PM
Borgeson BlakeDirectorOct 06 '26Proposed Sale4.8450,000242,000Oct 06 11:48 AM
HERSHBERG ROBERTDirectorOct 06 '26Proposed Sale5.0025,000125,000Oct 06 11:09 AM
Khan NajatCEO and PresidentSep 08 '26Sale3.5222,40878,8222,072,890Sep 10 05:55 PM
Najat KhanOfficerSep 08 '26Proposed Sale3.5222,40878,822Sep 08 02:28 PM
Borgeson BlakeDirectorSep 01 '26Sale3.3430,000100,2006,158,287Sep 02 06:01 PM
Borgeson BlakeDirectorSep 01 '26Proposed Sale3.3430,000100,200Sep 01 04:21 PM
Gibson ChristopherFormer DirectorAug 21 '26Proposed Sale3.3977,290262,013Aug 21 11:27 AM
Gibson ChristopherFormer DirectorAug 20 '26Proposed Sale3.4075,000255,000Aug 20 11:32 AM
Gibson ChristopherFormer DirectorAug 19 '26Proposed Sale3.27100,000327,500Aug 19 11:54 AM

Held by

AUM
TickerCompanyAUM
ARKEARK DIET Q3 Buffer ETFAUM: 1.45M
ARKKARK Innovation ETFAUM: 5.97B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
ARKGARK Genomic Revolution ETFAUM: 1.97B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 100
  • Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Iambic Therapeutics wins Bank of America backing with 194% upside forecast (Proactive) +8.10%
  • Recursion Beats On Milestone-Lifted Revenue, But Clinical De-Risking And A 2029 Runway Are The Real Story (Earnings Whispers)
  • Recursion Pharmaceuticals: Q3 Earnings Snapshot (Associated Press)
  • Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair (GlobeNewswire)
  • New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps (GlobeNewswire)
  • Recursion Appoints Fred Hassan as Chair of the Board (GlobeNewswire)
  • Recursion's Clinical Push Faces Test As Stock Rally Meets Leadership Questions And Lumpy Revenue (Earnings Whispers) +6.58%
  • Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3 (GlobeNewswire)
  • Iambic CEO on taking an AI drug company public (BioPharma Dive) -16.71%
  • RXRX Stock Heads For Its Best Day In Over A Year Whats Driving The Rally Today? (Stocktwits) +11.23%
  • Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration (GlobeNewswire)
  • Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock (GlobeNewswire)
  • Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-02-0.220-0.219-0.23318.0614.817
2026Q22026-08-05-0.250-0.240-0.2467.3010.977
2026Q12026-05-06-0.220-0.265-0.2226.3015.788
2025Q42026-02-25-0.210-0.301-0.20535.3524.547
2025Q32025-11-05-0.360-0.377-0.3634.9816.957
2025Q22025-08-05-0.410-0.353-0.41219.1015.376
2025Q12025-05-05-0.500-0.516-0.50314.8214.985
2024Q42025-02-28-0.530-0.411-0.5324.5115.317
2024Q32024-11-06-0.340-0.333-0.33926.0818.728
2024Q22024-08-08-0.400-0.384-0.40314.4011.967
2024Q12024-05-09-0.390-0.423-0.38713.4911.106
2023Q42024-02-27-0.420-0.449-0.39910.6219.908
2023Q32023-11-09-0.430-0.385-0.43410.1011.246
2023Q22023-08-08-0.380-0.375-0.38111.0211.877
2023Q12023-05-08-0.340-0.349-0.34112.1312.815
2022Q42023-02-27-0.310-0.290-0.31013.6823.804

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.815--0.5253.44-
2021FY-1.490-1.190-1.09510.0012.32
2022FY-1.360-1.407-1.36439.6848.26
2023FY-1.580-1.649-1.57843.8852.14
2024FY-1.690-1.539-1.69158.4970.75
2025FY-1.440-1.567-1.44074.2661.52
2026FY--0.881--38.76
2027FY--0.828--43.70
2028FY--0.764--37.80
2029FY--0.940--247.5

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-047237.762.0012.31
2026Q4S2026-11-037146.942.0012.00
2026Q4S2026-11-0271113.746.5830.40
2026Q4S2026-10-2071113.746.5830.40
2026Q4S2026-10-1972113.746.5830.40
2026Q4S2026-10-1472413.746.5830.40
2026Q4S2026-09-2171513.445.3030.40
2026Q4S2026-08-0772416.695.3030.40
2026Q4S2026-08-0671420.169.8037.30
2026Q4S2026-08-0570419.586.0037.30
2026Q4S2026-07-2170123.616.0037.30
2026Q4S2026-07-2071123.616.0037.30
2026Q4S2026-07-1872323.616.0037.30
2026Q4S2026-07-1072423.616.0037.30

Estimate history

EPS, annual-0.373-0.525-1.095-1.364-1.578-1.691-1.441-0.8925
Period2019202020212022202320242025TTM
EPS, quarterly-0.339-0.532-0.503-0.412-0.363-0.205-0.222-0.246-0.219
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual2.3193.96210.17839.84344.57558.83974.68168.23
Period2019202020212022202320242025TTM
Sales, quarterly26.0824.54614.74519.2235.17535.5386.4727.6718.552
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual165.791165.791170.272191.023234.27396.802528.183561.067
Period2019202020212022202320242025MRQ
Shares, quarterly286.124396.802406.411432.831491.801528.183530.629534.12561.067
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue68.2374.6858.8444.5839.8410.183.962.32
Cost of Goods Sold Incl. D&A95.50120.9563.4351.0948.659.10--
Gross Profit-27.27-46.27-4.59-6.51-8.811.07--
Selling, General and Administrative Excl. Other467.71601.86474.41343.55236.92183.8584.1461.22
Research and Development325.37425.27296.23232.73155.32134.9763.3245.81
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-494.98-648.13-479.00-350.06-245.73-182.78-84.61-62.44
Interest Expense-1.811.570.100.062.95--
Unusual Expense0.000.000.000.000.000.830.880.56
Net Income Before Taxes-480.23-644.89-464.79-332.13-239.48-186.48-87.01-61.88
Income Taxes-4.56-0.14-1.13-4.060.000.000.000.00
Consolidated Net Income-475.67-644.76-463.66-328.07-239.48-186.48-87.01-61.88
Net Income From Continuing Operations-475.67-644.76-463.66-328.07-239.48-186.48-87.01-61.88
Net Income-475.67-644.76-463.66-328.07-239.48-186.48-87.01-61.88
EPS (Recurring)-0.88-1.44-1.69-1.58-1.36-1.09-0.52-0.37
EPS (Basic, Before Extraordinaries)-0.89-1.44-1.69-1.58-1.36-1.10-0.52-0.37
EPS (Diluted)-0.89-1.44-1.69-1.58-1.36-1.10-0.52-0.37
EBITDA-421.13-564.43-442.51-317.60-226.24-173.67-80.17-58.90
Non-Operating Income (Expense)15.685.0515.7918.036.310.07-0.151.75
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense69.3486.9162.8151.6826.8713.833.841.39
Price To Sales Ratio32.8724.5031.5045.9833.97286.58--
Gross Margin-39.97-61.96-7.81-14.61-22.1110.55--
Operating Margin-725.44-867.87-814.09-785.33-616.74-1,795.79-2,135.66-2,692.58
Net Margin-697.13-863.35-788.02-735.99-601.05-1,832.18-2,196.01-2,668.35
Shares Outstanding561.07528.18396.80234.27191.02170.27165.79165.79
Market Capitalization2,237.892,237.892,641.552,128.621,461.482,886.132,945.10-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue18.557.676.4735.545.1719.2214.744.55
Cost of Goods Sold Incl. D&A20.2523.1925.1926.8828.0932.4633.5319.69
Gross Profit-1.69-15.52-18.728.66-22.91-13.24-18.78-15.14
Selling, General and Administrative Excl. Other121.48119.45109.79117.00149.29162.99172.58168.63
Research and Development88.9277.9175.2083.34107.66116.34117.9391.44
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-123.18-134.97-128.50-108.33-172.20-176.23-191.37-183.77
Interest Expense0.270.310.35-0.830.480.510.60
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-119.01-131.01-122.11-108.10-162.25-171.90-202.65-178.90
Income Taxes0.03-0.00-4.600.020.000.00-0.160.01
Consolidated Net Income-119.04-131.00-117.50-108.12-162.25-171.90-202.49-178.91
Net Income From Continuing Operations-119.04-131.00-117.50-108.12-162.25-171.90-202.49-178.91
Net Income-119.04-131.00-117.50-108.12-162.25-171.90-202.49-178.91
EPS (Recurring)-0.22-0.25-0.22-0.21-0.36-0.41-0.50-0.53
EPS (Basic, Before Extraordinaries)-0.22-0.25-0.22-0.21-0.36-0.41-0.50-0.53
EPS (Diluted)-0.22-0.25-0.22-0.21-0.36-0.41-0.50-0.53
EBITDA-106.64-116.80-108.83-88.86-151.16-152.38-172.04-170.67
Non-Operating Income (Expense)4.434.276.750.2310.794.81-10.775.47
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense18.0815.2517.3818.6319.7825.8028.1223.93
Price To Sales Ratio32.8735.6224.4728.8549.9332.6935.6438.61
Gross Margin-9.13-202.36-289.2224.37-442.74-68.87-127.39-333.08
Operating Margin-663.95-1,759.69-1,985.55-304.84-3,327.57-916.75-1,297.85-4,042.41
Net Margin-641.63-1,708.02-1,815.57-304.24-3,135.32-894.23-1,373.26-3,935.46
Shares Outstanding561.07534.12530.63528.18491.80432.83406.41396.80
Market Capitalization2,237.891,947.901,621.892,128.672,121.162,056.872,126.532,641.55

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments747.89597.39394.80551.19518.11267.1775.17
Short Term Receivables24.6549.173.092.759.090.160.15
Inventories0.000.000.000.000.000.000.00
Other Current Assets40.3167.7140.2515.877.512.151.08
Total Current Assets812.85714.27438.14569.81534.72269.4876.40
Net Property, Plant & Equipment169.48233.21120.17121.4564.7225.9724.37
Total Investments and Advances6.035.636.637.928.680.000.00
Intangible Assets472.06484.7388.502.112.192.490.00
Deferred Tax Assets55.181.93-----
Other Assets12.758.820.260.000.040.650.66
Total Assets1,528.361,448.60653.70701.29610.35298.58101.43
Short Term Debt Incl. Current Port. of LT Debt21.7522.226.166.051.511.540.54
Accounts Payable18.1221.613.954.592.821.071.26
Other Current Liabilities107.83143.6483.0689.6342.3320.484.88
Total Current Liabilities147.71187.4793.17100.2746.6623.106.68
Long Term Debt56.2186.2744.5244.969.9714.1215.62
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities77.4816.571.34----
Other Liabilities116.09123.5051.2470.2610.7819.342.28
Total Liabilities397.49413.82190.26215.4867.4156.5624.59
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00448.31201.11
Common Equity1,130.871,034.78463.44485.81542.94-206.29-124.27
Total Shareholders Equity1,130.871,034.78463.44485.81542.94242.0276.84
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity1,130.871,034.78463.44485.81542.94242.0276.84
Total Liabilities & Stockholders Equity1,528.361,448.60653.70701.29610.35298.58101.43
Book Value Per Share2.142.611.982.543.19-1.24-0.75
Tangible Book Value Per Share1.251.391.602.533.18-1.26-0.75
Full-Time Employees600800500500400216-
Price to Book Ratio2.223.684.853.465.374.92-
Return on Assets-43.32-44.11-48.42-36.52-41.03-43.50-
Return on Equity-59.54-61.89-69.12-46.56-47.51-54.57-
Return on Invested Capital-54.31-41.36-64.59-45.12-33.73-33.97-66.92
Quick Ratio5.503.814.705.6811.4611.6711.43
Current Ratio5.503.814.705.6811.4611.6711.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-475.67-644.76-463.66-328.07-239.48-186.48-87.01-61.88
Depreciation73.8583.7036.4932.4719.498.404.443.54
Other Funds (Non Cash)111.18175.56105.9958.0831.5519.776.330.89
Funds from Operations-290.63-385.50-321.17-237.52-188.44-158.31-76.23-57.45
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-19.8913.69-38.00-50.26104.92-0.3130.830.41
Cash from Operating Activities-310.53-371.81-359.17-287.78-83.52-158.61-45.40-57.04
Capital Expenditures-3.95-8.63-17.05-12.55-37.36-39.80-6.74-3.91
Net Assets From Acquisitions0.00-4.440.000.000.000.00-2.600.00
Sale of Fixed Assets and Businesses0.000.00277.101.840.000.00-0.00
Purchase or Sale of Investments0.00-3.810.000.48230.61-231.950.000.00
Purchase of Investments0.00-3.810.000.000.00-301.14--
Sale Or Maturity of Investments0.000.000.000.48230.6169.190.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.590.00
Cash from Investing Activities-3.95-16.87260.06-10.23193.25-271.74-8.74-3.91
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock219.69532.96308.56140.90154.44471.34239.81119.70
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock219.69532.96308.56140.90154.44471.34239.81119.70
Proceedsfrom Stock Options218.90528.86300.42128.09143.71462.90239.13119.64
Issuance or Reduction of Debt, Net-8.92-8.43-4.44-0.77-0.09-12.806.320.70
Change in Long Term Debt-8.92-8.43-4.44-0.77-0.09-12.806.320.70
Issuance of Long Term Debt0.000.000.000.000.000.006.4011.89
Reduction of Long Term Debt-8.92-8.43-4.44-0.77-0.09-12.80-0.08-11.18
Net Financing Active Other Cash Flow-0.35-3.000.000.000.000.000.000.00
Other Financing Activities Uses-0.35-3.000.000.000.000.000.000.00
Cash from Financing Activities210.41521.53304.12140.13154.34458.54246.13120.41
Exchange Rate Effect-1.5518.04-3.410.19----
Net Change in Cash-105.61150.90201.60-157.69264.0728.18192.0059.46
Free Cash Flow-312.48-378.28-372.87-299.74-120.58-198.41-51.23-60.95
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments556.51551.07659.98747.89662.97528.22
Short Term Receivables34.0614.3913.5924.6521.9121.61
Inventories0.000.000.000.000.000.00
Other Current Assets25.4538.0035.9940.3129.2237.34
Total Current Assets616.02603.46709.56812.85714.11587.16
Net Property, Plant & Equipment152.70147.07157.32169.48181.24193.60
Total Investments and Advances5.025.755.206.034.175.63
Intangible Assets434.39443.24454.24472.06484.39505.59
Deferred Tax Assets0.960.960.9655.180.960.96
Other Assets12.6312.1912.2512.7514.669.42
Total Assets1,221.711,212.671,339.521,528.361,399.531,302.36
Short Term Debt Incl. Current Port. of LT Debt24.0722.6922.3521.7520.4420.48
Accounts Payable16.3812.6720.3518.1213.9419.31
Other Current Liabilities82.4684.5287.00107.83120.72124.23
Total Current Liabilities122.92119.89129.70147.71155.10164.03
Long Term Debt50.6343.9550.0256.2161.9367.59
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities18.3718.3118.2877.4823.3123.78
Other Liabilities123.98115.52116.75116.09112.23127.81
Total Liabilities315.90297.67314.75397.49352.58383.21
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity905.81915.001,024.771,130.871,046.95919.15
Total Shareholders Equity905.81915.001,024.771,130.871,046.95919.15
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity905.81915.001,024.771,130.871,046.95919.15
Total Liabilities & Stockholders Equity1,221.711,212.671,339.521,528.361,399.531,302.36
Book Value Per Share1.611.711.932.142.132.12
Tangible Book Value Per Share0.840.881.081.251.140.96
Full-Time Employees---600--
Price to Book Ratio2.221.901.431.922.302.20
Return on Assets-36.29-41.26-42.33-43.32-67.31-62.47
Return on Equity-48.72-56.58-57.16-59.54-91.06-86.34
Return on Invested Capital-12.45-13.66-10.93-9.11-14.63-17.42
Quick Ratio5.015.035.475.504.603.58
Current Ratio5.015.035.475.504.603.58

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-119.04-131.00-117.50-108.12-162.25-171.90
Depreciation16.5418.1719.6719.4821.0423.85
Other Funds (Non Cash)29.3025.4524.5431.8950.1536.48
Funds from Operations-73.20-87.39-73.30-56.76-91.06-111.57
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.21-18.56-7.8010.68-26.3035.15
Cash from Operating Activities-77.41-105.95-81.10-46.07-117.36-76.42
Capital Expenditures-0.41-1.96-0.34-1.24-0.24-5.31
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.00-2.31-0.50
Purchase of Investments0.000.000.000.00-2.31-0.50
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.41-1.96-0.34-1.24-2.55-5.81
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock85.520.000.00134.17253.47102.74
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock85.520.000.00134.17253.47102.74
Proceedsfrom Stock Options85.24-0.981.26133.38254.46100.00
Issuance or Reduction of Debt, Net-2.29-2.25-2.21-2.17-2.13-2.08
Change in Long Term Debt-2.29-2.25-2.21-2.17-2.13-2.08
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-2.29-2.25-2.21-2.17-2.13-2.08
Net Financing Active Other Cash Flow-0.080.98-1.260.000.00-3.00
Other Financing Activities Uses-0.080.98-1.260.000.00-3.00
Cash from Financing Activities83.14-1.27-3.47132.01251.3497.66
Exchange Rate Effect-0.620.81-3.832.091.879.26
Net Change in Cash4.71-108.36-88.7486.78133.3024.69
Free Cash Flow-77.81-105.99-81.36-47.32-117.60-79.57

Revenue breakdown

Grant2024: 351.00K 2025: 425.00K
License and Service2024: 58.49M 2025: 74.26M
Other Countries2024: 327.00K
United Kingdom2024: 1.14M 2025: 35.34M
United States2024: 57.38M 2025: 39.34M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.40%142.3M560.1M22.06M
2026-10-1530.17%161.9M536.8M21.45M
2026-09-3032.81%157.9M481.4M19.66M
2026-09-1537.13%178.7M481.4M18.73M
2026-08-3137.30%179.1M480.3M20.02M
2026-08-1437.05%177.9M480.3M20.59M
2026-07-3137.65%180.8M480.1M20.63M
2026-07-1538.42%180.8M470.5M19.23M
2026-06-3036.62%172.3M470.5M16.48M
2026-06-1539.06%184.0M471.2M15.44M
2026-05-2935.00%164.3M469.5M14.00M
2026-05-1539.31%184.4M469.3M14.24M
2026-04-3036.52%171.3M469.1M15.68M
2026-04-1537.37%174.4M466.6M17.28M
2026-03-3137.36%173.9M465.5M18.91M
2026-03-1337.41%174.1M465.5M21.30M
2026-02-2736.75%168.5M458.6M21.96M
2026-02-1337.76%173.2M458.6M22.48M
2026-01-3037.86%165.5M437.3M25.08M
2026-01-1537.37%163.4M437.2M33.07M

Option chain

expiry 2026-11-13
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.502.583.553.0960.33913615.000.994-0.0170.000
call1.001.913.302.6039.30948672.000.990-0.0170.000
call1.501.612.502.0618.51042.0022.000.957-0.0550.000
call2.001.101.841.6310.76566.0025.000.939-0.0520.000
call2.500.611.371.128.24697.0016.000.912-0.0470.000
call3.000.001.080.538.16221.005.000.861-0.0400.001
call3.500.050.380.183.3271,1291,1690.598-0.0550.001
call4.000.010.020.011.3851,89861.000.120-0.0190.001
call4.500.000.010.012.0211,01225.000.085-0.0210.000
call5.000.000.010.012.7444830.000.066-0.0230.000
call5.500.000.050.053.1122413.000.034-0.0160.000
call6.000.000.150.083.61910.000.000.031-0.0170.000
call6.500.002.130.044.0673.001.000.028-0.0180.000
call7.000.000.050.104.1900.001.000.026-0.0170.000
call7.500.002.130.074.8413.002.000.024-0.0190.000
call8.000.002.130.025.1813.000.000.023-0.0200.000
call8.500.000.750.035.4964.003.000.022-0.0200.000
put0.500.000.010.0013.8650.000.00-0.006-0.0170.000
put1.000.000.010.018.5023.001.00-0.010-0.0150.000
put1.500.001.200.008.7430.000.00-0.043-0.0550.000
put2.000.001.350.006.2220.000.00-0.061-0.0520.000
put2.500.001.350.004.2460.000.00-0.088-0.0470.000
put3.000.000.050.012.5531710.00-0.139-0.0390.001
put3.500.030.090.061.30177533.00-0.402-0.0550.001
put4.000.000.780.425.1733071.00-0.873-0.0180.001
put4.500.531.420.977.9431421.00-0.948-0.0130.000
put5.000.811.901.488.8553.001.00-0.959-0.0150.000
put5.501.492.251.848.2110.001.00-0.966-0.0160.000
put6.002.002.752.408.9872.003.00-0.969-0.0170.000
put6.502.293.602.9713.3233.001.00-0.972-0.0170.000
put7.002.803.803.4010.8394.0010.00-0.974-0.0180.000
put7.503.405.954.7528.7084.008.00-0.976-0.0180.000
put8.003.856.454.5529.2003.006.00-0.977-0.0190.000
put8.503.856.955.0529.6543.0010.00-0.978-0.0190.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-11-044Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-043Initial statement of beneficial ownership of securities2026-10-31SEC
2026-11-03144Filing for proposed sale of securities under Rule 144.SEC
2026-11-0210-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-10-31SEC
2026-10-15424B5SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-15424B5SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-06SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-06144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-09-218-KCurrent report2026-09-15SEC
2026-09-164Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-08144Filing for proposed sale of securities under Rule 144.SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-19144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-18144Filing for proposed sale of securities under Rule 144.SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100155.20K1
2026-1000367.00K2
2026-0900179.02K2
2026-080097.50K1
2026-0700158.50K1
2026-0600367.79K5
2026-0500363.60K3
2026-0400361.40K3
2026-0300839.83K4
2026-02001.27M4
2026-01001.31M3
2025-12001.96M5
2025-1100374.80K2

Institutional holders

Manager% owned
BlackRock, Inc.9.48%
ARK Investment Management LLC7.79%
STATE STREET CORP6.54%
VANGUARD PORTFOLIO MANAGEMENT LLC5.87%
VANGUARD CAPITAL MANAGEMENT LLC4.29%
BAILLIE GIFFORD & CO3.39%
GEODE CAPITAL MANAGEMENT, LLC2.59%
SOFTBANK GROUP CORP.2.57%
FMR LLC2.13%
MIC Capital Management UK LLP1.82%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF4.17%
ARK Innovation ETF3.82%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.98%
ARK Genomic Revolution ETF2.57%
iShares Russell 2000 ETF2.47%
VANGUARD SMALL-CAP INDEX FUND2.15%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.24%
VANGUARD EXTENDED MARKET INDEX FUND1.13%
Fidelity Small Cap Index Fund1.05%
iShares Russell 2000 Value ETF0.82%

OakChart. RXRX. Cached 15 minutes.